It's been a banner year thus far for ADMA Biologics Inc. (ADMA) whose share price is up an impressive 168% year-to-date.
This fully integrated commercial biopharmaceutical company focuses on the manufacture and marketing of specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its marketed products include the FDA-approved ASCENIV, BIVIGAM and NABI-HB.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com